MicroRNA-630 is a prognostic marker for patients with colorectal cancer
MicroRNA-630 is a prognostic marker for patients with colorectal cancer
复制标题
MicroRNA-630 是结直肠癌患者的预后标志物。
DOI：
10.1007/s13277-014-2223-3
复制
发表时间：
2014-10-01
期刊：
影响因子：
--
通讯作者：
Ji, Gang
中科院分区：
文献类型：
--
作者：
Chu, Dake;Zheng, Jianyong;Ji, Gang
microRNA是在癌症进展期间调节多种细胞过程的非编码RNA。在各种microRNA中，miR-630最近被鉴定为与人类恶性肿瘤的许多关键过程有关。我们利用来自206例患者的癌组织和癌旁正常组织，研究了miR-630在人结直肠癌中的表达模式和预后价值。采用实时荧光定量PCR方法检测miR-630的表达，并采用适当的统计学分析方法评价miR-630与总生存期的相关性。结果发现，miR-630在结直肠癌组织中的表达明显高于癌旁正常组织。研究还证实miR-630在结直肠癌中的表达与肿瘤浸润、淋巴结转移、远处转移和TNM分期有关。Kaplan-Meier生存分析证明miR-630表达增加与结直肠癌患者的总生存率相关。多因素分析证实，在校正已知的预后因素后，miR-630是一个独立的预后标志物。这些结果证实了miR-630在人类结直肠癌中的过表达及其与肿瘤进展的相关性。这也表明miR-630表达可能作为结直肠癌患者的预后生物标志物。
MicroRNAs are noncoding RNAs that regulate multiple cellular processes during cancer progression. Among various microRNAs, miR-630 has recently been identified to be implicated in many critical processes in human malignancies. We investigated the expression pattern and prognostic value of miR-630 in human colorectal cancer by utilizing cancer and adjacent normal specimens from 206 patients. Quantitative real-time PCR assay was used to detect the expression of miR-630, and appropriate statistical analysis was used to evaluate the association of miR-630 with overall survival. It was found that miR-630 expression was significantly increased in colorectal cancer specimens compared with that in adjacent normal specimens. It was also proved that miR-630 expression in colorectal cancer was associated with tumor invasion, lymph node metastasis, distant metastasis, and tumor-node-metastasis (TNM) stage. The Kaplan-Meier survival analysis proved that increased miR-630 expression was associated with poor overall survival of patients with colorectal cancer. Multivariate analysis proved that miR-630 was an independent prognostic marker after adjusted for known prognostic factors. These results confirmed the overexpression of miR-630 in human colorectal cancer and its association with tumor progression. It also suggested that miR-630 expression might serve as a prognostic biomarker for patients with colorectal cancer.